A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus (ALE09)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Ajulemic acid (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 09 Aug 2017 According to a Corbus Pharmaceuticals media release, the study will begin in the fourth quarter of 2017.
- 06 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Aug 2017.
- 22 Mar 2017 Status changed from planning to not yet recruiting.